Companies Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International (KNSA): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Kiniksa Pharmaceuticals International, plc’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$10,782,661CEO Sanj Patel · source

Say-on-pay support97.3%Latest vote · source

CEO vs. named peers56th pct.Of 16 peer CEOs

CEO pay ratio35:1To the median employee · source

CEO pay, last three years

$5,297,067FY2023
$7,129,792FY2024
$10,782,661FY2025

CEO total pay was $10,782,661 in fiscal 2025, up from $7,129,792 in fiscal 2024.

FY2025: salary $943,129 · bonus $0 · stock awards $3,798,021 · option awards $4,743,446

Executives and directors

Eben Tessari · Executive John Paolini · EVP Mark Ragosa · CFO Ross Moat · COO Sanj Patel · CEO Barry D. Quart · Independent Director Felix J. Baker · Lead Independent Director G. Bradley Cole · Independent Director Kimberly J. Popovits · Independent Director M. Cantey Boyd · Independent Director Richard S. Levy · Independent Director Stephen R. Biggar · Independent Director Thomas R. Malley · Independent Director Tracey L. McCain · Independent Director

Frequently asked questions

Who was the highest-paid executive at Kiniksa Pharmaceuticals International, plc in fiscal 2025?

As disclosed, Sanj Patel (Chief Executive Officer and Chairman of the Board) was the highest-paid executive at Kiniksa Pharmaceuticals International, plc in fiscal 2025, with total compensation of $10,782,661.

How does Kiniksa Pharmaceuticals International, plc's chief executive pay compare to its disclosed peer group?

As disclosed, Sanj Patel's total compensation ranked at the 56th percentile of Kiniksa Pharmaceuticals International, plc's disclosed peer group.

What is Kiniksa Pharmaceuticals International, plc's CEO-to-median employee pay ratio?

As disclosed, Kiniksa Pharmaceuticals International, plc's CEO-to-median employee pay ratio was 35:1.

How did shareholders vote on Kiniksa Pharmaceuticals International, plc's executive compensation?

As disclosed, 97.3% of shareholders supported Kiniksa Pharmaceuticals International, plc's executive compensation in the latest say-on-pay vote.

How much does Kiniksa Pharmaceuticals International, plc spend in total on board compensation for fiscal 2025?

As disclosed, Kiniksa Pharmaceuticals International, plc reported total board compensation of $1,428,293 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Sanj Patel	$943,129	$0	$3,798,021	$4,743,446	$1,284,065	$0	$14,000	$10,782,661
Chief Executive Officer and Chairman of the Board
Ross Moat	586,269	0	1,084,019	1,356,609	533,326	0	77,778	3,638,001
Executive Vice President and Chief Commercial Officer
John Paolini	585,092	0	1,084,019	1,356,609	530,935	0	14,000	3,570,655
Executive Vice President and Chief Medical Officer
Eben Tessari	586,460	0	1,084,019	1,356,609	533,278	0	5,865	3,566,231
Executive Vice President and Chief Operating Officer
Mark Ragosa	552,795	0	978,099	1,221,456	516,705	0	14,000	3,283,055
Senior Vice President and Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Sanj Patel	$10,782,661	$7,129,792	$5,297,067	↑ +3,652,869
Ross Moat	3,638,001	2,337,130	1,631,209	↑ +1,300,871
John Paolini	3,570,655	2,431,016	1,789,109	↑ +1,139,639
Eben Tessari	3,566,231	2,353,166	1,752,096	↑ +1,213,065
Mark Ragosa	3,283,055	2,201,447	1,766,757	↑ +1,081,608

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is designed to reward the achievement of our strategic corporate objectives and creation of long-term shareholder value by emphasizing the achievement of short-term goals while sustaining long-term growth. We align executive interests with shareholders through a significant portion of target total direct compensation delivered in long-term equity awards, including performance-based awards, and ensure our pay practices are competitive with our peer group and industry.

CEO STI target (% of salary)	—
CEO LTI target (% of salary)	—
Independent consultant	Compensia, Inc.
Clawback policy	true
Anti-hedging	true
Anti-pledging	true

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Sanj Patel	PSU	2025-04-01	34,435	68,869	—	137,738	$1,895,143
Mark Ragosa	RSU	2025-04-01	—	—	7,382	—	160,706
Mark Ragosa	RSU	2025-09-01	—	—	12,275	—	411,090
Sanj Patel	RSU	2025-04-01	—	—	34,435	—	749,650
Sanj Patel	RSU	2025-09-01	—	—	34,435	—	1,153,228
Ross Moat	OPTION	2025-09-01	—	—	39,364	—	818,429
Ross Moat	RSU	2025-04-01	—	—	9,828	—	213,956
Ross Moat	RSU	2025-09-01	—	—	9,828	—	329,140
Ross Moat	PSU	2025-04-01	9,829	19,657	—	39,314	540,924
John Paolini	OPTION	2025-04-01	—	—	39,364	—	538,181
John Paolini	OPTION	2025-09-01	—	—	39,364	—	818,429
John Paolini	RSU	2025-04-01	—	—	9,828	—	213,956
John Paolini	RSU	2025-09-01	—	—	9,828	—	329,140
John Paolini	PSU	2025-04-01	9,829	19,657	—	39,314	540,924
Eben Tessari	RSU	2025-04-01	—	—	9,828	—	213,956
Eben Tessari	OPTION	2025-05-01	8,172	16,344	—	16,344	—
Eben Tessari	RSU	2025-09-01	—	—	9,828	—	329,140
Eben Tessari	PSU	2025-04-01	9,829	19,657	—	39,314	540,924
Mark Ragosa	OPTION	2025-04-01	—	—	29,480	—	403,048
Mark Ragosa	PSU	2025-04-01	7,383	14,765	—	29,530	406,303
Sanj Patel	OPTION	2025-04-01	—	—	137,638	—	1,878,082
Eben Tessari	OPTION	2025-09-01	—	—	39,364	—	818,429
Sanj Patel	OPTION	2025-09-01	—	—	137,638	—	2,861,673
Ross Moat	OPTION	2025-04-01	—	—	39,364	—	538,181
Eben Tessari	OPTION	2025-04-01	—	—	39,364	—	538,181
Mark Ragosa	OPTION	2025-09-01	—	—	39,363	—	818,408
John Paolini	PSU	2025-05-01	5,078	10,155	—	10,155	—
Ross Moat	PSU	2025-05-01	5,101	10,201	—	10,201	—
Ross Moat	OPTION	2025-05-01	8,173	16,346	—	16,346	—
John Paolini	OPTION	2025-05-01	8,137	16,273	—	16,273	—
Eben Tessari	PSU	2025-05-01	5,100	10,199	—	10,199	—
Mark Ragosa	PSU	2025-05-01	4,672	9,344	—	9,344	—
Mark Ragosa	OPTION	2025-05-01	7,487	14,974	—	14,974	—

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Sanj Patel	$1,902,878	$1,895,143	$4,739,755	22.2%
Mark Ragosa	571,796	406,303	1,221,456	18.5%
Ross Moat	543,096	540,924	1,356,610	22.2%
John Paolini	543,096	540,924	1,356,610	22.2%
Eben Tessari	543,096	540,924	1,356,610	22.2%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Ross Moat	RSU	2,477	—	$102,176
John Paolini	RSU	2,497	—	103,001
Mark Ragosa	RSU	2,694	—	111,128
Eben Tessari	RSU	2,726	—	112,448
Ross Moat	RSU	3,222	—	132,908
John Paolini	RSU	3,248	—	133,980
Mark Ragosa	RSU	3,500	—	144,375
Eben Tessari	RSU	3,545	—	146,231
Mark Ragosa	PSU	4,558	—	188,018
Mark Ragosa	RSU	4,773	—	196,886
Mark Ragosa	PSU	4,786	—	197,423
John Paolini	PSU	4,954	—	204,353
Ross Moat	Option	4,954	11.1	—
Eben Tessari	PSU	4,975	—	205,219
Ross Moat	PSU	4,976	—	205,260
John Paolini	Option	4,994	11.1	—
Mark Ragosa	PSU	5,092	—	210,045
John Paolini	PSU	5,201	—	214,541
Ross Moat	RSU	5,221	—	215,366
Eben Tessari	PSU	5,224	—	215,490
Ross Moat	PSU	5,225	—	215,531
Eben Tessari	RSU	5,235	—	215,944
John Paolini	RSU	5,250	—	216,563
Mark Ragosa	Option	5,388	11.1	—
Eben Tessari	Option	5,451	11.1	—
Ross Moat	PSU	5,569	—	229,721
Eben Tessari	PSU	5,585	—	230,381
John Paolini	PSU	5,600	—	231,000
Mark Ragosa	RSU	7,382	—	304,508
Sanj Patel	PSU	7,987	—	329,464
Sanj Patel	PSU	8,386	—	345,923
John Paolini	RSU	9,828	—	405,405
Eben Tessari	RSU	9,828	—	405,405
Ross Moat	RSU	9,828	—	405,405
Sanj Patel	RSU	9,991	—	412,129
Ross Moat	Option	11,148	11.97	—
John Paolini	Option	11,236	11.97	—
Mark Ragosa	Option	12,123	11.97	—
Eben Tessari	Option	12,266	11.97	—
Mark Ragosa	RSU	12,275	—	506,344
Ross Moat	Option	12,889	10.76	—
Sanj Patel	RSU	12,962	—	534,683
John Paolini	Option	12,991	10.76	—
Mark Ragosa	Option	14,016	10.76	—
Eben Tessari	Option	14,181	10.76	—
Mark Ragosa	PSU	14,765	—	609,056
Ross Moat	Option	16,916	17.76	—
John Paolini	Option	17,050	17.76	—
Mark Ragosa	Option	18,396	17.76	—
Eben Tessari	Option	18,612	17.76	—
Sanj Patel	RSU	18,712	—	771,870
Mark Ragosa	Option	19,337	18.06	—
John Paolini	PSU	19,657	—	810,851
Eben Tessari	PSU	19,657	—	810,851
Ross Moat	PSU	19,657	—	810,851
Sanj Patel	Option	19,982	11.1	—
Sanj Patel	PSU	20,000	—	825,000
Ross Moat	Option	21,058	18.06	—
Eben Tessari	Option	21,174	18.06	—
John Paolini	Option	21,203	18.06	—
Mark Ragosa	Option	22,790	26.74	—
Ross Moat	Option	24,818	26.74	—
Eben Tessari	Option	24,956	26.74	—
John Paolini	Option	24,990	26.74	—
Mark Ragosa	Option	29,480	21.77	—
Sanj Patel	RSU	34,435	—	1,420,444
Mark Ragosa	Option	39,363	33.49	—
John Paolini	Option	39,364	21.77	—
Eben Tessari	Option	39,364	21.77	—
Ross Moat	Option	39,364	21.77	—
John Paolini	Option	39,364	33.49	—
Eben Tessari	Option	39,364	33.49	—
Ross Moat	Option	39,364	33.49	—
Sanj Patel	Option	44,960	11.97	—
Sanj Patel	Option	51,832	10.76	—
Sanj Patel	Option	68,030	17.76	—
Sanj Patel	PSU	68,869	—	2,840,846
Sanj Patel	Option	75,686	18.06	—
Sanj Patel	Option	89,202	26.74	—
Sanj Patel	Option	137,638	21.77	—

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Richard S. LevyIndependent · Science (Chair)	$69,998	$111,470	$255,162	$0	$30,000	$466,630
Felix J. BakerIndependent · Lead Independent Director · Governance · Science	93,999	81,479	255,162	0	0	430,640
Barry D. QuartIndependent · Audit · Compensation · Science	77,999	81,479	255,162	0	0	414,640
Thomas R. MalleyIndependent · Audit (Chair) · Governance	74,999	81,479	255,162	0	0	411,640
Kimberly J. PopovitsIndependent · Compensation (Chair)	69,999	81,479	255,162	0	0	406,640
Stephen R. BiggarIndependent · Governance (Chair) · Science	68,999	81,479	255,162	0	0	405,640
G. Bradley ColeIndependent · Audit	59,999	81,479	255,162	0	0	396,640
Tracey L. McCainIndependent · Audit	59,999	81,479	255,162	0	0	396,640
M. Cantey BoydIndependent · Compensation	59,000	81,479	255,162	0	0	395,641
Sanj K. PatelEmployee director · Board Chair	—	—	—	—	—	0

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$340,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	20,000 / 20,000 / 10,000
Stock ownership guideline	—

Total cost of the board

Component	FY2025
Cash retainers and fees	$634,991
Equity awards (grant-date value)	$763,302
All other compensation	$30,000
Total cost of the board	$1,428,293

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Kiniksa Pharmaceuticals International as a peer

Companies that benchmark against KNSA

4 companies name KNSA as a compensation peer

Each company listed discloses KNSA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KNSA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

TVTX Travere TherapeuticsVCEL VericelBCRX BioCryst PharmaceuticalsACAD Acadia PharmaceuticalsAGIO Agios PharmaceuticalsFOLD Amicus TherapeuticsAPLS Apellis PharmaceuticalsARDX ArdelyxBBIO BridgeBio PharmaCORT Corcept TherapeuticsHRMY Harmony Biosciences HoldingsIRWD Ironwood PharmaceuticalsMGNX MacroGenicsRYTM Rhythm PharmaceuticalsSAGE Sage TherapeuticsSUPN Supernus Pharmaceuticals

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Rhythm Pharmaceuticals	2025	David Meeker	$807,692	$8,274,785	$7,688,560	$759,488	$17,544,525
2	Supernus Pharmaceuticals	2025	Jack Khattar	1,036,000	6,535,029	7,031,545	846,930	15,501,557
3	Corcept Therapeutics	2025	Joseph Belanoff	1,182,333	0	12,907,718	0	15,303,551
4	BridgeBio Pharma	2025	Neil Kumar	1,044,000	10,606,275	1,874,992	0	14,944,585
5	BioCryst Pharmaceuticals	2025	Jon Stonehouse	728,466	0	11,132,458	1,052,633	12,951,082
6	Vericel	2025	Dominick Colangelo	860,000	3,964,630	5,456,287	860,000	11,156,368
7	Apellis Pharmaceuticals	2024	Cedric Francois	793,193	4,779,832	4,787,768	0	10,957,451
8	Kiniksa Pharmaceuticals International, plc	2025	Sanj Patel	943,129	3,798,021	4,743,446	1,284,065	10,782,661
9	Amicus Therapeutics	2024	Bradley Campbell	767,308	4,990,365	2,105,627	0	8,526,943
10	Travere Therapeutics	2025	Eric Dube	854,250	3,314,520	3,309,384	964,125	8,457,151
11	Acadia Pharmaceuticals	2025	Catherine Owen Adams	930,000	3,240,558	3,234,797	818,559	8,256,518
12	Harmony Biosciences Holdings	2025	Jeffrey Dayno	743,600	1,976,520	4,599,000	558,000	7,899,535
13	Ardelyx	2025	Michael Raab	797,000	2,953,724	3,413,948	627,638	7,796,171
14	Sage Therapeutics	2024	Barry Greene	830,712	3,164,364	2,669,263	431,970	7,112,589
15	Agios Pharmaceuticals	2025	Brian Goff	846,864	1,291,680	2,627,252	592,804	5,370,389
16	MacroGenics	2025	Eric Risser	561,568	52,000	1,049,386	251,900	2,078,854
17	Ironwood Pharmaceuticals	2025	Thomas McCourt	867,568	411,696	0	650,676	1,948,390

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Kiniksa Pharmaceuticals International, plc	not disclosed	Option 50 · RSU 25 · PSU 25	not disclosed	Compensia, Inc.
Acadia Pharmaceuticals	110%	Options 50 · PSU 25 · RSU 25	Yes	Frederic W. Cook & Co., Inc. (FW Cook)
Agios Pharmaceuticals	100%	Option 40 · PSU 40 · RSU 20	No	Aon
Amicus Therapeutics	not disclosed	Option 33 · RSU 33 · PRSU 33	Yes — TSR Goal	Pay Governance
Apellis Pharmaceuticals	90.74%	RSU 50 · PSU 50	not disclosed	Pay Governance
Ardelyx	105%	Options 50 · RSU 50	not disclosed	Pearl Meyer
BioCryst Pharmaceuticals	not disclosed	not disclosed	not disclosed	Aon
BridgeBio Pharma	135%	RSU 50 · PSU 35 · Options 15	No	Aon Talent Solutions
Corcept Therapeutics	Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%%	Stock Options 100	not disclosed	not disclosed
Harmony Biosciences Holdings	100%	not disclosed	not disclosed	Pay Governance
Ironwood Pharmaceuticals	100%	RSU 50 · PSU 50	not disclosed	Alpine Rewards LLC
MacroGenics	85%	not disclosed	not disclosed	Alpine Rewards, LLC
Rhythm Pharmaceuticals	120%	Options 50 · RSU 50	No	Pay Governance
Sage Therapeutics	80%	not disclosed	Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index	Alpine Rewards
Supernus Pharmaceuticals	not disclosed	not disclosed	No	Aon
Travere Therapeutics	150%	not disclosed	No	Aon
Vericel	100%	Options 58 · RSU 42	not disclosed	FW Cook

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-05-29	48,145,082	1,334,278	8,495	97.3%	Passed
2025	2025-06-03	49,107,201	550,666	20,575	98.89%	Passed
2024	2024-06-05	46,903,551	469,616	324,979	99.01%	Passed
2023	2023-06-06	40,423,385	1,270,222	380,052	96.95%	Passed
2022	2022-06-29	41,519,436	333,395	56,571	99.2%	Passed
2021	2021-06-29	40,582,357	625,207	24,695	98.48%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-05-29	97.3%^a
2025	2025-06-03	98.89%^b
2024	2024-06-05	99.01%^c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.”.

b. Approved under the standard stated in the filing — “ Abstentions and broker non-votes will have no effect on the outcome of the vote on this proposal.”.

c. Approved under the standard stated in the filing — “ Abstentions and broker non-votes will have no effect on the outcome of the vote on this proposal.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	35 : 1
CEO total compensation	$10,782,661
Median employee compensation	$310,707

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Kimberly J. Popovits	Director	2026-05-29	A	12,158	$0	$0	Derivative, Class A Common	Form 4 ↗
Kimberly J. Popovits	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
Barry D. Quart	Director	2026-05-29	D	2,799	0	0	Derivative, Class A Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-29	A	36,474	0	0	Derivative, Class A Common	Form 4 ↗
Tracey L. McCain	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
G. Bradley Cole	Director	2026-05-29	D	2,799	0	0	Derivative, Class A Common	Form 4 ↗
G. Bradley Cole	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-29	D	2,799	0	0	Derivative, Class A Common	Form 4 ↗
Thomas R. Malley	Director	2026-05-29	A	2,026	0	0	Derivative, Class A Common	Form 4 ↗
Thomas R. Malley	Director	2026-05-29	A	12,158	0	0	Derivative, Class A Common	Form 4 ↗
Thomas R. Malley	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
Tracey L. McCain	Director	2026-05-29	D	2,799	0	0	Derivative, Class A Common	Form 4 ↗
Barry D. Quart	Director	2026-05-29	A	2,026	0	0	Derivative, Class A Common	Form 4 ↗
Barry D. Quart	Director	2026-05-29	A	12,158	0	0	Derivative, Class A Common	Form 4 ↗
Barry D. Quart	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
Tracey L. McCain	Director	2026-05-29	A	12,158	0	0	Derivative, Class A Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-29	A	36,474	0	0	Derivative, Class A Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-29	A	6,078	0	0	Common	Form 4 ↗
G. Bradley Cole	Director	2026-05-29	A	12,158	0	0	Derivative, Class A Common	Form 4 ↗
Richard S. Levy	Director	2026-05-29	A	2,026	0	0	Derivative, Class A Common	Form 4 ↗
Tracey L. McCain	Director	2026-05-29	A	2,026	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-06-01	D	900,000	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-06-01	A	900,000	—	—	Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	14,000	0	0	Derivative, Class A Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	82,600	0	0	Derivative, Class A Common	Form 4 ↗
Dividend-equivalent accruals		2026-07-01	—	2,552	—	—	1 insider, 2 accrual rows
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	2,188	0	0	Derivative, Class A Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	2,119	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-07-15	A	279	34	9,347	Common	Form 4 ↗
G. Bradley Cole	Director	2026-07-29	D	3,673	81	299,092	Common	Form 4 ↗
G. Bradley Cole	Director	2026-07-29	D	4,500	0	0	Common	Form 4 ↗
Dividend-equivalent accruals		2026-08-01	—	806	—	—	1 insider, 2 accrual rows
Richard S. Levy	Director	2026-08-01	A	403	—	—	Common	Form 4 ↗
Barry D. Quart	Director	2026-08-19	D	2,600	0	0	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	2,644	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	5,531	79	438,498	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	2,362	—	—	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	D	2,477	0	0	Derivative, Class A Common	Form 4 ↗
Dividend-equivalent accruals		2026-09-01	—	10,066	—	—	3 insiders, 6 accrual rows
Ross Moat	Chief Operating Officer	2026-09-01	A	36,950	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	1,611	—	—	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	D	2,457	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	D	4,029	79	319,419	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	1,624	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	120,150	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	8,609	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	9,991	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	6,237	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	8,609	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	6,237	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	6,481	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	9,991	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	31,150	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	7,800	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	D	4,404	79	349,149	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	3,069	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	1,591	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	1,750	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	2,694	—	—	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	D	4,007	79	317,675	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	1,740	—	—	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	3,650	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	2,457	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	9,991	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	6,237	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	8,609	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	6,237	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	6,481	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	9,991	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	6,481	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	8,609	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	120,150	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	30,050	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	D	2,497	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	26,750	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	2,457	—	—	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	1,750	—	—	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	2,497	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	D	2,694	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	D	3,069	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	D	2,457	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	3,932	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	2,558	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	2,362	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	14,600	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	2,558	—	—	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	3,932	—	—	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	2,644	—	—	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	2,477	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	6,481	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	30,050	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	15,144	79	1,200,616	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	15,144	79	1,200,616	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	9,250	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	6,700	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-03	D	4,600	80	369,380	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	10,895	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	16,112	0	0	Derivative, Class A Common	Form 4 ↗
Dividend-equivalent accruals		2026-10-30	—	1,658	—	—	1 insider, 1 accrual row
Ross Moat	Chief Operating Officer	2026-10-30	D	3,760	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	21,059	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	16,111	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	2,575	98	251,732	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	1,760	97	170,896	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	3,672	96	352,622	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	6,282	95	596,287	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	8,430	94	792,167	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	15,114	93	1,402,730	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	37,775	92	3,475,300	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	10,895	18	196,764	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	16,112	18	286,149	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	1,658	13	21,504	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	3,760	12	45,007	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	21,059	11	233,755	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	16,111	11	173,354	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	39,042	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	38,545	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	2,155	98	210,694	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	1,925	97	186,841	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	4,000	96	383,880	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	4,821	95	457,320	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	6,841	94	642,438	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	16,056	93	1,490,800	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	41,789	92	3,845,424	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	A	39,042	18	699,633	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	A	38,545	31	1,192,197	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	47,530	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	1,440	98	141,350	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	2,316	97	225,439	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	4,490	96	430,905	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	8,888	95	841,871	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	15,903	94	1,488,839	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	18,685	93	1,733,407	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	41,169	92	3,787,960	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	A	47,530	9	419,690	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	4,065	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	4,689	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	7,209	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	3,932	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	5,350	98	522,909	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	1,691	97	164,213	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	3,145	96	302,172	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	3,705	95	351,456	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	9,508	94	895,654	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	6,831	93	633,712	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	6,030	92	553,976	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	A	4,065	18	72,194	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	A	7,209	12	86,292	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	A	3,932	11	43,645	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	A	4,689	11	50,454	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	6,263	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	12,302	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	9,412	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	722	94	67,904	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	11,642	93	1,084,452	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	8,932	92	822,191	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	6,681	91	609,508	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	A	6,263	23	143,360	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	A	12,302	22	267,815	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	A	9,412	18	169,981	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	9,636	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	12,123	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	5,388	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	9,636	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	220	94	20,682	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	12,034	93	1,120,726	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	10,502	92	966,499	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	14,027	91	1,282,068	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	A	9,636	18	171,135	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	A	12,123	12	145,112	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	A	5,388	11	59,807	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	A	9,636	11	103,683	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	11,958	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	6,455	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	704	94	66,239	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	16,810	93	1,570,390	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	899	92	83,041	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	A	11,958	18	214,287	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	A	6,455	31	199,653	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	53,381	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	100	94	9,397	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	26,781	93	2,492,240	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	24,188	92	2,221,184	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	38,364	91	3,492,275	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	A	53,381	9	471,354	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	41,237	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	89,089	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	4,584	94	432,042	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	145,708	94	13,628,069	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	68,664	93	6,365,153	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	1,214	91	110,195	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	A	41,237	18	738,967	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	A	89,089	9	786,656	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 200 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Kimberly J. Popovits	Director	2026-05-29	A	12,158	$0	$0	Derivative, Class A Common	Form 4 ↗
Kimberly J. Popovits	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
Barry D. Quart	Director	2026-05-29	D	2,799	0	0	Derivative, Class A Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-29	A	36,474	0	0	Derivative, Class A Common	Form 4 ↗
Tracey L. McCain	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
G. Bradley Cole	Director	2026-05-29	D	2,799	0	0	Derivative, Class A Common	Form 4 ↗
G. Bradley Cole	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
Richard S. Levy	Director	2026-05-29	D	2,799	0	0	Derivative, Class A Common	Form 4 ↗
Thomas R. Malley	Director	2026-05-29	A	2,026	0	0	Derivative, Class A Common	Form 4 ↗
Thomas R. Malley	Director	2026-05-29	A	12,158	0	0	Derivative, Class A Common	Form 4 ↗
Thomas R. Malley	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
Tracey L. McCain	Director	2026-05-29	D	2,799	0	0	Derivative, Class A Common	Form 4 ↗
Barry D. Quart	Director	2026-05-29	A	2,026	0	0	Derivative, Class A Common	Form 4 ↗
Barry D. Quart	Director	2026-05-29	A	12,158	0	0	Derivative, Class A Common	Form 4 ↗
Barry D. Quart	Director	2026-05-29	A	2,799	—	—	Common	Form 4 ↗
Tracey L. McCain	Director	2026-05-29	A	12,158	0	0	Derivative, Class A Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-29	A	36,474	0	0	Derivative, Class A Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-29	A	6,078	0	0	Common	Form 4 ↗
G. Bradley Cole	Director	2026-05-29	A	12,158	0	0	Derivative, Class A Common	Form 4 ↗
Richard S. Levy	Director	2026-05-29	A	2,026	0	0	Derivative, Class A Common	Form 4 ↗
Tracey L. McCain	Director	2026-05-29	A	2,026	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-06-01	D	900,000	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-06-01	A	900,000	—	—	Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	14,000	0	0	Derivative, Class A Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	82,600	0	0	Derivative, Class A Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	1,307	0	0	Derivative, Class A Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	1,245	0	0	Derivative, Class A Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	2,188	0	0	Derivative, Class A Common	Form 4 ↗
Dhiraj H. Malkani	Chief Strategy Officer	2026-07-01	A	2,119	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-07-15	A	279	34	9,347	Common	Form 4 ↗
G. Bradley Cole	Director	2026-07-29	D	3,673	81	299,092	Common	Form 4 ↗
G. Bradley Cole	Director	2026-07-29	D	4,500	0	0	Common	Form 4 ↗
Richard S. Levy	Director	2026-08-01	A	403	0	0	Derivative, Class A Common	Form 4 ↗
Richard S. Levy	Director	2026-08-01	D	403	0	0	Derivative, Class A Common	Form 4 ↗
Richard S. Levy	Director	2026-08-01	A	403	—	—	Common	Form 4 ↗
Barry D. Quart	Director	2026-08-19	D	2,600	0	0	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	2,644	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	5,531	79	438,498	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	2,362	—	—	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	D	2,477	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	D	1,611	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	D	1,740	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	36,950	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	1,611	—	—	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	D	1,624	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	D	1,750	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	D	2,457	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	D	4,029	79	319,419	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	1,624	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	120,150	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	8,609	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	9,991	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	6,237	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	8,609	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	6,237	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	6,481	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	9,991	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	D	1,591	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	31,150	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	7,800	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	D	4,404	79	349,149	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	3,069	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	1,591	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	1,750	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	A	2,694	—	—	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	D	4,007	79	317,675	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	1,740	—	—	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	3,650	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	2,457	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	9,991	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	6,237	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	8,609	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	6,237	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	6,481	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	9,991	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	6,481	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	8,609	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	120,150	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	30,050	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	D	2,497	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	26,750	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	2,457	—	—	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	1,750	—	—	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	2,497	—	—	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	D	2,694	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	D	1,750	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-09-01	D	3,069	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	D	2,457	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	3,932	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	2,558	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	D	2,362	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	14,600	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	2,558	—	—	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	3,932	—	—	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-01	A	2,644	—	—	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	2,477	—	—	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	6,481	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	A	30,050	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	15,144	79	1,200,616	Common	Form 4 ↗
Sanj K. Patel	Director	2026-09-01	D	15,144	79	1,200,616	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-09-01	A	9,250	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-09-01	A	6,700	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-09-03	D	4,600	80	369,380	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	10,895	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	16,112	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	1,658	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	3,760	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	21,059	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	16,111	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	2,575	98	251,732	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	1,760	97	170,896	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	3,672	96	352,622	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	6,282	95	596,287	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	8,430	94	792,167	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	15,114	93	1,402,730	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	D	37,775	92	3,475,300	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	10,895	18	196,764	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	16,112	18	286,149	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	1,658	13	21,504	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	3,760	12	45,007	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	21,059	11	233,755	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-10-30	A	16,111	11	173,354	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	39,042	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	38,545	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	2,155	98	210,694	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	1,925	97	186,841	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	4,000	96	383,880	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	4,821	95	457,320	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	6,841	94	642,438	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	16,056	93	1,490,800	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	D	41,789	92	3,845,424	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	A	39,042	18	699,633	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-10-30	A	38,545	31	1,192,197	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	47,530	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	1,440	98	141,350	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	2,316	97	225,439	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	4,490	96	430,905	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	8,888	95	841,871	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	15,903	94	1,488,839	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	18,685	93	1,733,407	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	D	41,169	92	3,787,960	Common	Form 4 ↗
Sanj K. Patel	Director	2026-10-30	A	47,530	9	419,690	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	4,065	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	4,689	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	7,209	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	3,932	0	0	Derivative, Class A Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	5,350	98	522,909	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	1,691	97	164,213	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	3,145	96	302,172	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	3,705	95	351,456	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	9,508	94	895,654	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	6,831	93	633,712	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	D	6,030	92	553,976	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	A	4,065	18	72,194	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	A	7,209	12	86,292	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	A	3,932	11	43,645	Common	Form 4 ↗
Michael R. Megna	Chief Accounting Officer	2026-10-30	A	4,689	11	50,454	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	6,263	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	12,302	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	9,412	0	0	Derivative, Class A Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	722	94	67,904	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	11,642	93	1,084,452	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	8,932	92	822,191	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	D	6,681	91	609,508	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	A	6,263	23	143,360	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	A	12,302	22	267,815	Common	Form 4 ↗
Ross Moat	Chief Operating Officer	2026-11-02	A	9,412	18	169,981	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	9,636	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	12,123	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	5,388	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	9,636	0	0	Derivative, Class A Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	220	94	20,682	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	12,034	93	1,120,726	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	10,502	92	966,499	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	D	14,027	91	1,282,068	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	A	9,636	18	171,135	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	A	12,123	12	145,112	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	A	5,388	11	59,807	Common	Form 4 ↗
Mark Ragosa	Chief Financial Officer	2026-11-02	A	9,636	11	103,683	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	11,958	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	6,455	0	0	Derivative, Class A Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	704	94	66,239	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	16,810	93	1,570,390	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	D	899	92	83,041	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	A	11,958	18	214,287	Common	Form 4 ↗
John Paolini	Chief Medical Officer	2026-11-02	A	6,455	31	199,653	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	53,381	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	100	94	9,397	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	26,781	93	2,492,240	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	24,188	92	2,221,184	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	D	38,364	91	3,492,275	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-02	A	53,381	9	471,354	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	41,237	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	89,089	0	0	Derivative, Class A Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	4,584	94	432,042	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	145,708	94	13,628,069	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	68,664	93	6,365,153	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	D	1,214	91	110,195	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	A	41,237	18	738,967	Common	Form 4 ↗
Sanj K. Patel	Director	2026-11-03	A	89,089	9	786,656	Common	Form 4 ↗

Sources (272 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Sanj Patel. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 10,782,661. View filing ↗
Section 01, Ross Moat. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 3,638,001. View filing ↗
Section 01, John Paolini. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 3,570,655. View filing ↗
Section 01, Eben Tessari. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 3,566,231. View filing ↗
Section 01, Mark Ragosa. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 3,283,055. View filing ↗
Section 03, Sanj Patel PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Mark Ragosa RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Mark Ragosa RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Sanj Patel RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Sanj Patel RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Ross Moat OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Ross Moat RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Ross Moat RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Ross Moat PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, John Paolini OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, John Paolini OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, John Paolini RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, John Paolini RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, John Paolini PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Eben Tessari RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Eben Tessari OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Eben Tessari RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Eben Tessari PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Mark Ragosa OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Mark Ragosa PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Sanj Patel OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Eben Tessari OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Sanj Patel OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Ross Moat OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Eben Tessari OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Mark Ragosa OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, John Paolini PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Ross Moat PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Ross Moat OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, John Paolini OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Eben Tessari PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Mark Ragosa PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 03, Mark Ragosa OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-16. Section “CEO Pay Ratio”. As printed: 35 : 1. View filing ↗
Section 08, Richard S. Levy. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 466,630. View filing ↗
Section 08, Felix J. Baker. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 430,640. View filing ↗
Section 08, Barry D. Quart. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 414,640. View filing ↗
Section 08, Thomas R. Malley. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 411,640. View filing ↗
Section 08, Kimberly J. Popovits. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 406,640. View filing ↗
Section 08, Stephen R. Biggar. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 405,640. View filing ↗
Section 08, G. Bradley Cole. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 396,640. View filing ↗
Section 08, Tracey L. McCain. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 396,640. View filing ↗
Section 08, M. Cantey Boyd. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 395,641. View filing ↗
Section 08, Sanj K. Patel. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Kimberly J. Popovits 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kimberly J. Popovits 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Barry D. Quart 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tracey L. McCain 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, G. Bradley Cole 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, G. Bradley Cole 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Thomas R. Malley 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Thomas R. Malley 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Thomas R. Malley 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tracey L. McCain 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Barry D. Quart 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Barry D. Quart 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Barry D. Quart 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tracey L. McCain 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, G. Bradley Cole 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tracey L. McCain 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-07-15. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, G. Bradley Cole 2026-07-29. Form 4, filed 2026-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, G. Bradley Cole 2026-07-29. Form 4, filed 2026-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-08-01. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-08-01. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Richard S. Levy 2026-08-01. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Barry D. Quart 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-05-29. Item 5.07 · say-on-pay result. As reported: 97.3% (votes for as printed: 48,145,082). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-03. Item 5.07 · say-on-pay result. As reported: 98.89% (votes for as printed: 49,107,201). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-06-05. Item 5.07 · say-on-pay result. As reported: 99.01% (votes for as printed: 46,903,551). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 634,991 + equity 763,302 + all other 30,000 = 1,428,293, summed across the director compensation table rows.
Rhythm Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals's own proxy. As printed: 17,544,525. View filing ↗
Supernus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. View filing ↗
Corcept Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. View filing ↗
BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
BioCryst Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. View filing ↗
Vericel, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. View filing ↗
Apellis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. View filing ↗
Kiniksa Pharmaceuticals International, plc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Kiniksa Pharmaceuticals International, plc's own proxy. As printed: 10,782,661. View filing ↗
Amicus Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. View filing ↗
Travere Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. View filing ↗
Acadia Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals's own proxy. As printed: 8,256,518. View filing ↗
Harmony Biosciences Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Harmony Biosciences Holdings's own proxy. As printed: 7,899,535. View filing ↗
Ardelyx, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. View filing ↗
Sage Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. View filing ↗
Agios Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. View filing ↗
MacroGenics, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics's own proxy. As printed: 2,078,854. View filing ↗
Ironwood Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. View filing ↗